Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric Xenografts
Authors:
- 28 May 2008
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (8) , 2301-2309
Abstract
S-1 is the most effective oral fluoropyrimidine derivative widely used for patients with gastric carcinoma in Japan. Although S-1 plus taxane has been a promising candidate as an effective chemotherapeutic regimen, the mechanisms of its additive or synergistic anticancer effects and changes in gene expression after the administration of these agents have not yet been fully elucidated. Experimental chemotherapy was performed using human gastric carcinoma xenografts, MKN-45 and TMK-1, to examine anticancer effects and gene expressions of fluoropyrimidine metabolism-related enzymes including thymidine phosphorylase (TP), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), and uridine phosphorylase (UP). Nude mice were treated with S-1, paclitaxel, and their combination. After treatment, in vivo antitumor effects of S-1, paclitaxel alone, and their combination and the effects on gene expressions of enzymes involved in 5-fluorouracil metabolism were examined using the RT-PCR method. The combined use of S-1 and paclitaxel showed additive to synergistic antitumor effects on both gastric cancer xenografts. While consistent upregulation of dThPase and DPD gene expression was exhibited after administration of S-1, no further increase of dThPase gene expression after combined use of S-1 with paclitaxel was observed. There was no increase in TS gene expression after the administration of either S-1 alone or paclitaxel alone. These results provide some insight into the mechanism and/or rationale underlying the additive to synergistic effect of combined administration of S-1 and paclitaxel in gastric carcinoma.Keywords
This publication has 33 references indexed in Scilit:
- Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancerBritish Journal of Cancer, 2006
- Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancerBritish Journal of Cancer, 2006
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancerGastric Cancer, 2006
- Phase I Evaluation of Continuous 5-Fluorouracil Infusion Followed by Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric CancerJapanese Journal of Clinical Oncology, 2005
- Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NUGastric Cancer, 2004
- Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancerGastric Cancer, 2002
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998
- First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trialEuropean Journal of Cancer, 1997
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.Journal of Cell Biology, 1992
- Thymidylate synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyuridylateBiochemical and Biophysical Research Communications, 1972